Recent 8-K filings for CBLL

• August 10, 2026, 4:27 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Ceribell Q2 revenue up 33% to $28.1M; raises FY2026 guidance to $114-117M

  Total revenue $28.1M, up 33% YoY; product revenue $21.2M, subscription $6.9M.

• July 29, 2026, 7:00 PM ET leadership materiality 0.30 neutral item 5.02

  CeriBell adds two new directors, rebalances board classes

  Board increased from 7 to 9; Sharon L. O'Keefe and Thomas A. West elected as Class I directors.

• June 2, 2026, 4:19 PM ET other material materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×2

  CeriBell stockholders elect Parvizi and Robertson as Class II directors, ratify PwC as auditor

  At June 2, 2026 annual meeting, Josef Parvizi, M.D., Ph.D. elected with 25,961,193 votes for, 2,311,420 withheld, 4,374,728 broker non-votes.

• May 11, 2026, 4:16 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Ceribell Q1 revenue $26.5M (+29% YoY); raises FY2026 guidance to $112-116M

  Revenue $26.5M, up 29% YoY; product $20.2M, subscription $6.3M, both +29%.

• February 24, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Ceribell Q4 revenue $24.8M (+34% YoY); FY 2026 guidance $111-115M

  Full-year 2025 revenue $89.1M (+36% YoY); net loss $53.4M ($1.46/share).

• January 5, 2026, 6:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Ceribell receives FDA Breakthrough Device Designation for LVO stroke detection system

  FDA Breakthrough Device Designation granted for CeriBell's LVO stroke detection and monitoring solution.

• January 2, 2026, 6:59 PM ET leadership materiality 0.25 neutral item 5.02item 9.01

  CeriBell director Lucian Iancovici resigns from Board, effective Dec. 31, 2025

  Lucian Iancovici resigned from CeriBell Board and committee roles, effective Dec. 31, 2025.

• December 12, 2025, 6:59 PM ET other material materiality 0.30 neutral item 1.01item 9.01 ◈ Material Agreements ×2

  Ceribell extends two Sunnyvale CA leases to Jan 2028; monthly rent ~$109k

  625 N. Pastoria lease extended one year to Jan 2028; monthly rent $34,821.

• December 9, 2025, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Ceribell receives FDA 510(k) clearance for first delirium monitoring solution

  FDA cleared Ceribell's EEG-based delirium screening and monitoring system for critically ill patients.

• November 24, 2025, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Ceribell receives FDA 510(k) clearance for Clarity algorithm to detect seizures in neonates

  FDA clearance covers use of Clarity algorithm for electrographic seizure detection in newborns preterm and older through adults, the first AI-powered point-of-care EEG for all ages.

• November 4, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Ceribell Q3 revenue $22.6M (+31% YoY); raises FY 2025 guidance to $87-89M

  Product revenue $17.0M (+28%); subscription revenue $5.6M (+44%).

• September 24, 2025, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 9.01

  Ceribell adds Vietnam manufacturing facility for headbands via Everwin Amendment No. 3

  Amendment No. 3 designates Everwin Vietnam as agent to deliver headbands from facility in Nghe An, Vietnam.

• September 22, 2025, 7:59 PM ET leadership materiality 0.50 positive item 5.02item 9.01

  Erica Rogers appointed to Ceribell Board; former Silk Road Medical CEO brings medtech scaling expertise

  Erica Rogers elected to Board effective Sept 17, 2025, and appointed to Compensation Committee.

• August 5, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Ceribell Q2 revenue $21.2M (+38% YoY); raises FY2025 guidance to $85-88M

  Total revenue $21.2M, up 38% YoY from $15.3M; product revenue $15.9M, subscription $5.3M.

• July 7, 2025, 7:59 PM ET litigation materiality 0.55 neutral item 8.01item 9.01

  CeriBell files patent infringement lawsuits against Natus Medical with USITC and Delaware court

  Filed complaints at USITC and Delaware District Court alleging infringement of six CeriBell patents.

• June 20, 2025, 7:59 PM ET other material materiality 0.60 positive item 1.01item 9.01

  Ceribell exercises option to extend Stanford license exclusivity through patent expiration for $250K

  Exercised option on June 12, 2025 to extend exclusive license for brain wave detection devices.

• June 12, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

  CeriBell shareholders elect two Class I directors, ratify PwC as auditor

  Juliet Tammenoms Bakker elected with 20,199,817 votes for, 2,031,435 withheld.

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Ceribell Q1 revenue $20.5M (+42% YoY); raises FY2025 guidance to $83-87M

  Q1 total revenue $20.5M (+42% YoY); product $15.6M (+41%), subscription $4.9M (+45%).

• April 11, 2025, 7:59 PM ET other material materiality 0.75 negative item 7.01item 9.01

  CeriBell sees 8-10 ppt gross margin drag from 145% China tariffs after Q3 2025

  FY2024 gross margin 87%; tariffs on Chinese-sourced goods expected to reduce margin by 8-10 percentage points.

• March 14, 2025, 7:59 PM ET other materiality 0.30 neutral item 5.02item 9.01

  CeriBell raises CEO, CFO, CTO base salaries and incentive targets effective April 1, 2025

  CEO Xingjuan (Jane) Chao annual base salary increased to $685,000 and target annual incentive to 95% of base.

• February 25, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Ceribell Q4 revenue $18.5M (+41% YoY); FY2024 revenue $65.4M (+45%); guides FY2025 $81-85M

  Q4 revenue $18.5M (+41% YoY); product $14.1M, subscription $4.4M; gross margin 88%.

• January 13, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Ceribell presents at J.P. Morgan Healthcare Conference; no financial updates disclosed

  Ceribell scheduled to present at 2025 J.P. Morgan Annual Healthcare Conference on January 13, 2025.

• November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Ceribell Q3 revenue $17.2M (+48% YoY); net loss $10.4M; guides FY2024 rev $64.2-64.7M

  Product revenue $13.3M (+52%), subscription revenue $3.9M (+36%).

• October 15, 2024, 7:59 PM ET other material materiality 0.85 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  CeriBell closes IPO of 12.2M shares at $17.00, gross proceeds ~$207.3M

  IPO of 12,196,969 shares (including 1,590,909 overallotment shares) closed on Oct 15, 2024 at $17.00 per share.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

14 positive 1 negative 9 neutral

source · CBLL on sec.gov